Effects of short-term orlistat therapy on maximal power production capacity in obese patients

colak, ramis; TÜRKOĞLU, A. Baki; ÖZÇELİK, Oğuz

Effects of short-term orlistat therapy on maximal power production capacity in obese patients

Oğuz ÖZÇELİK, (Fırat Üniversitesi, Tıp Fakültesi, Fizyoloji Anabilim Dalı, Elazığ, Türkiye)

Ramis ÇOLAK, (Girilmedi)

A. Baki TÜRKOĞLU (Girilmedi)

Turkish Journal of Medical Sciences

0 0

Yıl: 2002 Cilt: 32 Sayı: 6 Sayfa Aralığı: 493 - 497 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Effects of short-term orlistat therapy on maximal power production capacity in obese patients

Öz:

The aim of this study was to examine the effects of weight loss induced by hypocaloric diet and orlistat therapy for a four-week period on maximal work rate (Wmax) production capacity and aerobic fitness in obese patients. Fifteen obese subjects were given an integrated energy restricted diet and orlistat supplement (DO). Each patient performed two incremental ramp exercise tests using an electromagnetically braked cycle ergometer: one at the beginning and one at the end of the four-weeks to determine Wmax production capacity. Four weeks of DO therapy resulted in a significant reduction in total body weight (93.7 ± 14.6 kg vs. 90.3 ± 13.5 kg, P = 0.0001) and body fat mass (37.8 ± 6.4 kg vs. 35.9 ± 7.1 kg, P = 0.003). However, weight reduction achieved during DO therapy was not associated with increased Wmax production capacity: 100 ± 31 W (basal) vs. 103 ± 31 W (four-week) (P = 0.3) and aerobic fitness: 69.2 ± 19 W (basal) vs 66.7 ± 19 W (four-week) (P = 0.5). Body weight reduction without improving obese patients' Wmax production capacity during the DO therapy period indicates that physicians should consider an exercise training program, which is expected to improve obese patients' functional capacity.

Anahtar Kelime: Exercise Test Obesity Diet Therapy Exercise Body Mass Index Weight Loss

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 67: 968-977, 1983.
2. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 119: 655-660, 1993.
3. Jung RT: Obesity as a disease. Br Med Bull 53: 307-321, 1997.
4. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 16: 397-415, 1992.
5. Uusitupa M. New aspects in management of obesity: operation and impact of lipase inhibitors. Curr Opin Lipidol 10: 3-7, 1999.
6. James WP, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes Relat Metab Disord 21: 24S-30S, 1997.
7. Davidson MH, Hauptman J, Di Girolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomised controlled trial. JAMA 20: 235-242, 1999.
8. Blair SN, Kohl III HW, Barlow CE, Paffenbarger RS Jr, Gibbons LW, Macera CA. Changes in physical fitness and allcause mortality. A prospective study of healthy and unhealthy men. JAMA 273: 1093-1098, 1995.
9. Jebb S., Moore MS. Contribution of a sedentary lifestyle and inactivity to the etiology of overweight and obesity: current evidence and research issues. Med Sci Sports Exerc 31: 534S-541S, 1999.
10. Utter AC, Nieman DC, Ward AN, Butterworth DE. Use of the leg-to-leg bioelectrical impedance method in assessing body-composition change in obese women. Am J Clin Nutr 69: 603-607, 1999.
11. Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Clin Pharmacol 54: 125-132, 1998.
12. Whipp BJ, Davis JA, Torres F, Wasserman K. A test to determine parameters of aerobic function during exercise. J Appl Physiol 50: 217-221, 1981.
13. Wasserman K, Whipp BJ, Casaburi R, Oren A. Coupling of ventilation to metabolism during exercise. In: Exercise bioenergetics and gas exchange, Eds. Ceretelli, Whipp, Elsevier, Amsterdam 1980, 159-174.
14. Wasserman K, Whipp BJ. Exercise physiology in health and disease. Am Rev Respir Dis 112: 219-249, 1975.
15. Miller WC, Wallace JP, Eggert KE. Predicting max HR and HR-VO2 relationship for exercise prescription in obesity. Med Sci Sports Exerc 25: 1077-1081, 1991.
16. Hansen JE, Sue DY, Wasserman K. Predicted values for clinical exercise testing. Am Rev Respir Dis 129: 49-55, 1984.
17. Jones NL, Makrides L, Hitchcock C, Chypcar T, McCartney N. Normal standards for an incremental progressive cycle ergometer test. Am Rev Respir Dis 131: 700-708, 1985.
18. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 74: 761-811, 1994.
19. Nakajima T, Fujioka S, Tokunaga K, Matsuzawa Y, Tarui S. Correlation of intra-abdominal fat accumulation and left ventricular performance in obesity. Am J Cardiol 64: 369-373, 1989.
20. Babb TG, Korzick D, Meador M, Hodgson JL, Buskirk ER. Ventilatory response of moderate obese women to submaximal exercise. Int J Obes 15: 59- 65, 1991.
21. Wasserman K, Hansen JE, Sue DY, Whipp BJ. Principles of exercise testing and interpretation (Ed. JM Harris) Lea & Febiger Publisher: Philadelphia, 1994 pp: 52-72.
22. Van Gaal LF, Wauters MA, De Leeuw ICH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 21: 5S-9S, 1997.
23. Erikssen G, Liestol K, Bjornholt J, Thaulow E, Sandvik L, Erikssen J. Changes in physical fitness and changes in mortality. Lancet 352: 759-762, 1998.
24. Lee CD, Jackson AS, Blair SN. US weight guidelines: is it also important to consider cardiorespiratory fitness? Int J Obes Relat Metab Disord 22: 2S-7S, 1998.
25. Lee IM, Hsieh CC, Paffenbarger RS Jr. Exercise intensity and longevity in men. The Harvard Alumni Health Study. JAMA 273: 1179-1184, 1995.
26. Barlow CE, Kohl HW, Gibbons LW, Blair SN. Physical fitness, mortality and obesity. Int J Obes Relat Metab Disord 19: 41S-44S, 1995.
27. Grundy SM, Blackburn G, Higgins M, Lauer R, Perri MG, Ryan D. Physical activity in the prevention and treatment of obesity and its comorbidities: evidence report of independent panel to assess the role of physical activity in the treatment of obesity and its comorbidities. Med Sci Sports Exerc 31: 1493- 1500, 1999.
28. Lee CD, Blair SN, Jackson AS. Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men. Am J Clin Nutr 69: 373-380, 1999.
29. Alexander JK, Amad KH, Cole VW. Observations on some clinical features of extreme obesity, with particular reference to circulatory effect. Am J Med 32: 512-524, 1962.
30. Salvadori A, Fanari P, Fontana M, Buontempi L, Saezza A, Baudo S, Miserocchi G, Longhini E. Oxygen uptake and cardiac performance in obese and normal subjects during exercise. Respiration 66: 25-33, 1999

APA	ÖZÇELİK O, colak r, TÜRKOĞLU A (2002). Effects of short-term orlistat therapy on maximal power production capacity in obese patients. , 493 - 497.
Chicago	ÖZÇELİK Oğuz,colak ramis,TÜRKOĞLU A. Baki Effects of short-term orlistat therapy on maximal power production capacity in obese patients. (2002): 493 - 497.
MLA	ÖZÇELİK Oğuz,colak ramis,TÜRKOĞLU A. Baki Effects of short-term orlistat therapy on maximal power production capacity in obese patients. , 2002, ss.493 - 497.
AMA	ÖZÇELİK O,colak r,TÜRKOĞLU A Effects of short-term orlistat therapy on maximal power production capacity in obese patients. . 2002; 493 - 497.
Vancouver	ÖZÇELİK O,colak r,TÜRKOĞLU A Effects of short-term orlistat therapy on maximal power production capacity in obese patients. . 2002; 493 - 497.
IEEE	ÖZÇELİK O,colak r,TÜRKOĞLU A "Effects of short-term orlistat therapy on maximal power production capacity in obese patients." , ss.493 - 497, 2002.
ISNAD	ÖZÇELİK, Oğuz vd. "Effects of short-term orlistat therapy on maximal power production capacity in obese patients". (2002), 493-497.

APA	ÖZÇELİK O, colak r, TÜRKOĞLU A (2002). Effects of short-term orlistat therapy on maximal power production capacity in obese patients. Turkish Journal of Medical Sciences, 32(6), 493 - 497.
Chicago	ÖZÇELİK Oğuz,colak ramis,TÜRKOĞLU A. Baki Effects of short-term orlistat therapy on maximal power production capacity in obese patients. Turkish Journal of Medical Sciences 32, no.6 (2002): 493 - 497.
MLA	ÖZÇELİK Oğuz,colak ramis,TÜRKOĞLU A. Baki Effects of short-term orlistat therapy on maximal power production capacity in obese patients. Turkish Journal of Medical Sciences, vol.32, no.6, 2002, ss.493 - 497.
AMA	ÖZÇELİK O,colak r,TÜRKOĞLU A Effects of short-term orlistat therapy on maximal power production capacity in obese patients. Turkish Journal of Medical Sciences. 2002; 32(6): 493 - 497.
Vancouver	ÖZÇELİK O,colak r,TÜRKOĞLU A Effects of short-term orlistat therapy on maximal power production capacity in obese patients. Turkish Journal of Medical Sciences. 2002; 32(6): 493 - 497.
IEEE	ÖZÇELİK O,colak r,TÜRKOĞLU A "Effects of short-term orlistat therapy on maximal power production capacity in obese patients." Turkish Journal of Medical Sciences, 32, ss.493 - 497, 2002.
ISNAD	ÖZÇELİK, Oğuz vd. "Effects of short-term orlistat therapy on maximal power production capacity in obese patients". Turkish Journal of Medical Sciences 32/6 (2002), 493-497.